Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.43 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22637680 | 1.00 | HDAC6 (0.43) | HDAC6HDAC1HDAC8HDAC5S1PR1 | |
| SCHEMBL22637681 | 1.00 | HDAC6 (0.43) | HDAC6HDAC1HDAC8HDAC5S1PR1 | |
| SCHEMBL22637906 | 0.88 | S1PR1 (0.55) | HDAC6HDAC1HDAC8HDAC5S1PR1 | |
| SCHEMBL29478734 | 0.88 | S1PR1 (0.55) | HDAC6HDAC1HDAC8HDAC5S1PR1 | |
| SCHEMBL24660777 | 0.88 | S1PR1 (0.55) | HDAC6HDAC1HDAC8HDAC5S1PR1 | |
| SCHEMBL24660471 | 0.88 | S1PR1 (0.55) | HDAC6HDAC1HDAC8HDAC5S1PR1 | |
| SCHEMBL22637496 | 0.85 | S1PR1 (0.46) | HDAC6HDAC1HDAC8S1PR1ACACB | |
| SCHEMBL22637495 | 0.85 | S1PR1 (0.46) | HDAC6HDAC1HDAC8S1PR1ACACB | |
| SCHEMBL29478788 | 0.85 | S1PR1 (0.46) | HDAC6HDAC1HDAC8S1PR1ACACB | |
| SCHEMBL34466001 | 0.84 | S1PR1 (0.47) | HDAC6HDAC1HDAC8HDAC5S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583849-B2 | KCNT1 inhibitors and methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4692069-A2 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4110317-B1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
| EP-4110317-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-115443129-A | KCNT1 inhibitors and methods of use | 普拉西斯精密医药公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-114269340-A | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583849-B2 | KCNT1 inhibitors and methods of use | KCNT1, SCN1A, KCNT2 | HDAC6 1219/4885HDAC1 769/4885HDAC8 1336/4885 |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | HDAC6 1167/4885HDAC1 1680/4885HDAC8 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.